Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 28.60
- Piotroski Score 3.00
- Grade Overweight
- Symbol (GPCR)
- Company Structure Therapeutics Inc.
- Price $30.08
- Changes Percentage (-8.04%)
- Change -$2.63
- Day Low $29.93
- Day High $33.75
- Year High $66.38
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $93.00
- High Stock Price Target $118.00
- Low Stock Price Target $65.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.25
- Trailing P/E Ratio -23.59
- Forward P/E Ratio -23.59
- P/E Growth -23.59
- Net Income $-89,620,000
Income Statement
Quarterly
Annual
Latest News of GPCR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
Cantor analyst Josh Schimmer and JP Morgan analyst Eric Joseph initiated coverage on biopharma company Septerna (SEPN) with an Overweight rating. Schimmer highlights SEPN's innovative GPCR-targeting p...
By Yahoo! Finance | 2 days ago -
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?
The article discusses the market trends and investment strategies amidst volatility, focusing on the performance of small-cap vs. large-cap stocks. Analysts emphasize a balanced approach, with insight...
By Yahoo! Finance | 1 month ago -
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Investing in unprofitable businesses like biotech and mining exploration companies can be profitable, but risks exist. Analyzing Structure Therapeutics, its cash burn rate is low compared to cash rese...
By Yahoo! Finance | 3 months ago
